REFERENCES
1. Cancer. World Health Organization. Available from: https://www.who.int/health-topics/cancer. [Last accessed on 13 March 2024].
2. Types of cancer treatment. National Cancer Institute. Available from: https://www.cancer.gov/about-cancer/treatment/types. [Last accessed on 13 March 2024].
3. Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci 2021;22:9451.
4. Cancer drugs A to Z list. Cancer Research UK. Available from: https://www.cancerresearchuk.org/about-cancer/treatment/drugs. [Last accessed on 13 March 2024].
5. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 2017;7:339-48.
6. Wang C, Xu X, Xiong S, et al. Calcium-chelated nanosystem reversing cancer chemoresistance via replenishing intracellular calcium ions. Chem Eng J 2022;448:137500.
7. Büsselberg D, Florea AM. Targeting intracellular calcium signaling ([Ca2+]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers 2017;9:48.
8. Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013;4:28.
10. Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42.
12. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 2008;8:361-75.
13. Prevarskaya N, Ouadid-Ahidouch H, Skryma R, Shuba Y. Remodelling of Ca2+ transport in cancer: how it contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol Sci 2014;369:20130097.
14. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 2007;7:519-30.
15. Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta 2015;1848:2502-11.
17. Bong AHL, Monteith GR. Calcium signaling and the therapeutic targeting of cancer cells. Biochim Biophys Acta Mol Cell Res 2018;1865:1786-94.
19. Tajada S, Villalobos C. Calcium permeable channels in cancer hallmarks. Front Pharmacol 2020;11:968.
20. Wu Y, Huang P, Dong XP. Lysosomal calcium channels in autophagy and cancer. Cancers 2021;13:1299.
21. Yáñez M, Gil-Longo J, Campos-Toimil M. Calcium binding proteins. Adv Exp Med Biol 2012;740:461-82.
23. Čendula R, Chomaničová N, Adamičková A, Gažová A, Kyselovič J, Máťuš M. Altered expression of ORAI and STIM isoforms in activated human cardiac fibroblasts. Physiol Res 2021;70:S21-30.
24. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 2007;7:690-702.
25. Zheng S, Wang X, Zhao D, Liu H, Hu Y. Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications. Trends Cell Biol 2023;33:312-23.
26. Prole DL, Taylor CW. Structure and function of IP3 receptors. Cold Spring Harb Perspect Biol 2019;11:a035063.
27. Wu L, Lian W, Zhao L. Calcium signaling in cancer progression and therapy. FEBS J 2021;288:6187-205.
28. Bujak JK, Kosmala D, Szopa IM, Majchrzak K, Bednarczyk P. Inflammation, cancer and immunity-implication of TRPV1 channel. Front Oncol 2019;9:1087.
29. Liang JL, Tsai MH, Hsieh YC, et al. TRPC7 facilitates cell growth and migration by regulating intracellular Ca2+ mobilization in lung adenocarcinoma cells. Oncol Lett 2023;25:92.
30. Brandalise F, Ramieri M, Pastorelli E, et al. Role of Na+/Ca2+ exchanger (NCX) in glioblastoma cell migration (in vitro). Int J Mol Sci 2023;24:12673.
31. Loeck T, Schwab A. The role of the Na+/Ca2+-exchanger (NCX) in cancer-associated fibroblasts. Biol Chem 2023;404:325-37.
32. Curry MC, Luk NA, Kenny PA, Roberts-Thomson SJ, Monteith GR. Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J Biol Chem 2012;287:28598-608.
33. Stafford N, Wilson C, Oceandy D, Neyses L, Cartwright EJ. The plasma membrane calcium ATPases and their role as major new players in human disease. Physiol Rev 2017;97:1089-125.
35. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21.
36. Kumari N, Gaur H, Bhargava A. Cardiac voltage gated calcium channels and their regulation by β-adrenergic signaling. Life Sci 2018;194:139-49.
37. Fernandez Garcia E, Paudel U, Noji MC, et al. The mitochondrial Ca2+ channel MCU is critical for tumor growth by supporting cell cycle progression and proliferation. Front Cell Dev Biol 2023;11:1082213.
38. Samanta K, Mirams GR, Parekh AB. Sequential forward and reverse transport of the Na+ Ca2+ exchanger generates Ca2+ oscillations within mitochondria. Nat Commun 2018;9:156.
39. Pizzo P, Lissandron V, Capitanio P, Pozzan T. Ca2+ signalling in the Golgi apparatus. Cell Calcium 2011;50:184-92.
40. Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer 2017;17:367-80.
41. Alhamed AS, Alqinyah M, Alsufayan MA, et al. Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response. Saudi Pharm J 2023;31:245-54.
42. Phan NN, Wang CY, Chen CF, Sun Z, Lai MD, Lin YC. Voltage-gated calcium channels: novel targets for cancer therapy. Oncol Lett 2017;14:2059-74.
43. Ardura JA, Álvarez-Carrión L, Gutiérrez-Rojas I, Alonso V. Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers 2020;12:1071.
44. Danese A, Leo S, Rimessi A, et al. Cell death as a result of calcium signaling modulation: a cancer-centric prospective. Biochim Biophys Acta Mol Cell Res 2021;1868:119061.
45. Um HD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget 2016;7:5193-203.
46. Patergnani S, Danese A, Bouhamida E, et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int J Mol Sci 2020;21:8323.
47. Zhivotovsky B, Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 2011;50:211-21.
48. Pedrera L, Ros U, García-Sáez AJ. Calcium as a master regulator of ferroptosis and other types of regulated necrosis. Cell Calcium 2023;114:102778.
49. Hernández-Oliveras A, Zarain-Herzberg A. The role of Ca2+-signaling in the regulation of epigenetic mechanisms. Cell Calcium 2024;117:102836.
50. Hernández-Oliveras A, Zarain-Herzberg Á. Expression and associated epigenetic mechanisms of the Ca2+-signaling genes in breast cancer subtypes and epithelial-to-mesenchymal transition. J Cell Commun Signal 2022;16:461-74.
51. Raynal NJ, Lee JT, Wang Y, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res 2016;76:1494-505.
52. Alam MR, Rahman MM, Li Z. The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy. Genes Dis 2024;11:321-34.
53. Savina A, Vidal M, Colombo MI. The exosome pathway in K562 cells is regulated by Rab11. J Cell Sci 2002;115:2505-15.
54. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010;120:457-71.
55. Wang CY, Lai MD, Phan NN, Sun Z, Lin YC. Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients. PLoS One 2015;10:e0125766.
56. Tang BD, Xia X, Lv XF, et al. Inhibition of Orai1-mediated Ca2+ entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5-fluorouracil. J Cell Mol Med 2017;21:904-15.
57. Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M. 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene 2013;32:4529-38.
58. Zhou X, Wang W, Zhang S, et al. CACNA1B (Cav2.2) overexpression and its association with clinicopathologic characteristics and unfavorable prognosis in non-small cell lung cancer. Dis Markers 2017;2017:6136401.
59. Passaia BDS, Kremer JL, Fragoso MCV, Lotfi CFP. N-type calcium channel v2.2 is a target of TCF21 in adrenocortical carcinomas. Neoplasma 2022;69:899-908.
60. Li G, Roy B, Huang X, et al. High expression of N-type calcium channel indicates a favorable prognosis in gliomas. Medicine 2022;101:e29782.
61. Cai X, Yu X, Yang J, et al. TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC. Hepatol Commun 2023;7:e0101.
62. Wang T, Li N, Jin L, Qi X, Zhang C, Hua D. The calcium pump PMCA4 prevents epithelial-mesenchymal transition by inhibiting NFATc1-ZEB1 pathway in gastric cancer. Biochim Biophys Acta Mol Cell Res 2020;1867:118833.
63. Lee AR, Park CY. Orai1 is an entotic Ca2+ channel for non-apoptotic cell death, entosis in cancer development. Adv Sci 2023;10:e2205913.
64. Kianfar M, Balcerak A, Chmielarczyk M, Tarnowski L, Grzybowska EA. Cell death by entosis: triggers, molecular mechanisms and clinical significance. Int J Mol Sci 2022;23:4985.
65. Rupert C, Dell’ Aversana C, Mosca L, et al. Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models. J Exp Clin Cancer Res 2023;42:134.
66. Zhai X, Sterea AM, Hiani YE. Lessons from the endoplasmic reticulum Ca2+ transporters-a cancer connection. Cells 2020;9:1536.
67. Wang X, Li Y, Li Z, et al. Mitochondrial calcium uniporter drives metastasis and confers a targetable cystine dependency in pancreatic cancer. Cancer Res 2022;82:2254-68.
69. Marmolejo-Garza A, Krabbendam IE, Luu MDA, et al. Negative modulation of mitochondrial calcium uniporter complex protects neurons against ferroptosis. Cell Death Dis 2023;14:772.
70. Liu Y, Jin M, Wang Y, et al. MCU-induced mitochondrial calcium uptake promotes mitochondrial biogenesis and colorectal cancer growth. Signal Transduct Target Ther 2020;5:59.
71. Makena MR, Ko M, Mekile AX, et al. Secretory pathway Ca2+-ATPase SPCA2 regulates mitochondrial respiration and DNA damage response through store-independent calcium entry. Redox Biol 2022;50:102240.
72. Feng M, Grice DM, Faddy HM, et al. Store-independent activation of Orai1 by SPCA2 in mammary tumors. Cell 2010;143:84-98.
73. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287:31666-73.
74. Scotto Rosato A, Montefusco S, Soldati C, et al. TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway. Nat Commun 2019;10:5630.
75. Zawadzki A, Liu Q, Wang Y, Melander A, Jeppsson B, Thorlacius H. Verapamil inhibits L-type calcium channel mediated apoptosis in human colon cancer cells. Dis Colon Rectum 2008;51:1696-702.
76. Li S, Kim HY, Lee DJ, et al. Inhibition of L-type voltage-gated calcium channel-mediated Ca2+ influx suppresses the collective migration and invasion of ameloblastoma. Cell Prolif 2022;55:e13305.
77. Sun J, Sun X, Li Z, Ma D, Lv Y. An elongated tract of polyQ in the carboxyl-terminus of human α1A calcium channel induces cell apoptosis by nuclear translocation. Oncol Rep 2020;44:156-64.
78. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992;89:3825-9.
79. Mergler S, Wiedenmann B, Prada J. R-type Ca2+-channel activity is associated with chromogranin A secretion in human neuroendocrine tumor BON cells. J Membr Biol 2003;194:177-86.
80. Sekar S, Subbamanda Y, Pullaguri N, et al. Isoform-specific expression of T-type voltage-gated calcium channels and estrogen receptors in breast cancer reveals specific isoforms that may be potential targets. Curr Res Biotechnol 2022;4:459-67.
81. Zhang Y, Cruickshanks N, Yuan F, et al. Targetable T-type calcium channels drive glioblastoma. Cancer Res 2017;77:3479-90.
82. Pottle J, Sun C, Gray L, Li M. Exploiting MCF-7 cells’ calcium dependence with interlaced therapy. J Cancer Ther 2013;4:32-40.
83. Rim HK, Cho S, Shin DH, et al. T-type Ca2+ channel blocker, KYS05090 induces autophagy and apoptosis in A549 cells through inhibiting glucose uptake. Molecules 2014;19:9864-75.
84. Kumari N, Bhargava A, Rath SN. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line. Life Sci 2020;260:118291.
85. Kumari N, Giri PS, Rath SN. Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel. Cancer Drug Resist 2021;4:996-1007.
86. Huang W, Lu C, Wu Y, Ouyang S, Chen Y. T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines. J Exp Clin Cancer Res 2015;34:54.
87. Asghar MY, Lassila T, Paatero I, et al. Stromal interaction molecule 1 (STIM1) knock down attenuates invasion and proliferation and enhances the expression of thyroid-specific proteins in human follicular thyroid cancer cells. Cell Mol Life Sci 2021;78:5827-46.
88. Kim MS, Kim SH, Yang SH, Kim MS. Afatinib mediates autophagic degradation of ORAI1, STIM1, and SERCA2, which inhibits proliferation of non-small cell lung cancer cells. Tuberc Respir Dis 2022;85:147-54.
89. Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J Cell Physiol 2011;226:542-51.
90. Kouba S, Buscaglia P, Guéguinou M, et al. Pivotal role of the ORAI3-STIM2 complex in the control of mitotic death and prostate cancer cell cycle progression. Cell Calcium 2023;115:102794.
91. Chen SJ, Hoffman NE, Shanmughapriya S, et al. A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2α. J Biol Chem 2014;289:36284-302.
92. Peterson JA, Crowther CM, Andrus MB, Kenealey JD. Resveratrol derivatives increase cytosolic calcium by inhibiting plasma membrane ATPase and inducing calcium release from the endoplasmic reticulum in prostate cancer cells. Biochem Biophys Rep 2019;19:100667.
93. Curry M, Roberts-Thomson SJ, Monteith GR. PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263. Biochem Biophys Res Commun 2016;478:1792-7.
94. Cruz P, Ahumada-Castro U, Bustos G, et al. Inhibition of insP3R with xestospongin B reduces mitochondrial respiration and induces selective cell death in T cell acute lymphoblastic leukemia cells. Int J Mol Sci 2021;22:651.
95. Lorenzo-Anota HY, Reyes-Ruiz A, Calvillo-Rodríguez KM, et al. IMMUNEPOTENT CRP increases intracellular calcium through ER-calcium channels, leading to ROS production and cell death in breast cancer and leukemic cell lines. EXCLI J 2023;22:352-66.
96. Harvey KE, Tang S, LaVigne EK, Pratt EPS, Hockerman GH. RyR2 regulates store-operated Ca2+ entry, phospholipase C activity, and electrical excitability in the insulinoma cell line INS-1. PLoS One 2023;18:e0285316.
97. Pathak T, Gueguinou M, Walter V, et al. Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis. Elife 2020;9:e59686.
98. Pera E, Kaemmerer E, Milevskiy MJG, et al. The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell Int 2016;16:24.
99. VanHouten J, Sullivan C, Bazinet C, et al. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc Natl Acad Sci U S A 2010;107:11405-10.
100. Ma X, Chen Z, Hua D, et al. Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc Natl Acad Sci U S A 2014;111:6389-94.
101. Ma X, Cai Y, He D, et al. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci U S A 2012;109:16282-7.
102. Ni Y, Zhou X, Yang J, et al. The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front Cell Dev Biol 2021;9:637675.
103. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019;51:27-41.
104. Bergmeier W, Weidinger C, Zee I, Feske S. Emerging roles of store-operated Ca2+ entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels 2013;7:379-91.
105. Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 2020;13:100773.
106. Davis FM, Azimi I, Faville RA, et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 2014;33:2307-16.
107. Klabunde T, Hessler G. Drug design strategies for targeting g-protein-coupled receptors. ChemBioChem 2002;3:928-44.
108. Dhyani V, Gare S, Gupta RK, Swain S, Venkatesh KV, Giri L. GPCR mediated control of calcium dynamics: a systems perspective. Cell Signal 2020;74:109717.
109. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
110. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
111. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
112. Lee H, Kim JW, Kim DK, et al. Calcium channels as novel therapeutic targets for ovarian cancer stem cells. Int J Mol Sci 2020;21:2327.
114. Cheng Q, Chen A, Du Q, et al. Novel insights into ion channels in cancer stem cells (review). Int J Oncol 2018;53:1435-41.
115. Sui X, Geng JH, Li YH, Zhu GY, Wang WH. Calcium channel α2δ1 subunit (CACNA2D1) enhances radioresistance in cancer stem-like cells in non-small cell lung cancer cell lines. Cancer Manag Res 2018;10:5009-18.
116. Forostyak O, Forostyak S, Kortus S, Sykova E, Verkhratsky A, Dayanithi G. Physiology of Ca2+ signalling in stem cells of different origins and differentiation stages. Cell Calcium 2016;59:57-66.
117. Lu H, Chen I, Shimoda LA, et al. Chemotherapy-induced Ca2+ release stimulates breast cancer stem cell enrichment. Cell Rep 2017;18:1946-57.
118. Yanagida E, Shoji S, Hirayama Y, et al. Functional expression of Ca2+ signaling pathways in mouse embryonic stem cells. Cell Calcium 2004;36:135-46.
119. Lee SH, Rigas NK, Lee CR, et al. Orai1 promotes tumor progression by enhancing cancer stemness via NFAT signaling in oral/oropharyngeal squamous cell carcinoma. Oncotarget 2016;7:43239-55.
120. Shiozaki A, Kudou M, Ichikawa D, et al. Esophageal cancer stem cells are suppressed by tranilast, a TRPV2 channel inhibitor. J Gastroenterol 2018;53:197-207.
121. Morelli MB, Nabissi M, Amantini C, et al. The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int J Cancer 2012;131:E1067-77.
122. Okuno K, Xu C, Pascual-Sabater S, et al. Andrographis reverses gemcitabine resistance through regulation of ERBB3 and calcium signaling pathway in pancreatic ductal adenocarcinoma. Biomedicines 2023;11:119.
123. Yunos NM, Mutalip SSM, Jauri MH, Yu JQ, Huq F. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines. Anticancer Res 2013;33:4365-71.
124. Sharma P, Shimura T, Banwait JK, Goel A. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis 2020;41:1385-94.
125. Zhou J, Ong CN, Hur GM, Shen HM. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol 2010;79:1242-50.
126. Li W, Zhang M, Xu L, Lin D, Cai S, Zou F. The apoptosis of non-small cell lung cancer induced by cisplatin through modulation of STIM1. Exp Toxicol Pathol 2013;65:1073-81.
127. Kondratska K, Kondratskyi A, Yassine M, et al. Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. Biochim Biophys Acta 2014;1843:2263-9.
128. Gualdani R, de Clippele M, Ratbi I, Gailly P, Tajeddine N. Store-operated calcium entry contributes to cisplatin-induced cell death in non-small cell lung carcinoma. Cancers 2019;11:430.
129. Flourakis M, Lehen’kyi V, Beck B, et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis 2010;1:e75.
130. Peters AA, Milevskiy MJ, Lee WC, et al. The calcium pump plasma membrane Ca2+-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. Sci Rep 2016;6:25505.
131. Dziegielewska B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK. T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer Ther 2016;15:460-70.
132. Granados K, Hüser L, Federico A, et al. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. Br J Cancer 2020;122:1023-36.
133. Zhang JY, Zhang PP, Zhou WP, et al. L-type cav 1.2 calcium channel-α-1C regulates response to rituximab in diffuse large B-cell lymphoma. Clin Cancer Res 2019;25:4168-78.
134. Das A, Pushparaj C, Bahí N, et al. Functional expression of voltage-gated calcium channels in human melanoma. Pigment Cell Melanoma Res 2012;25:200-12.
135. Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology 2014;76:175-83.
136. Kumari N, Dalal V, Kumar P, Rath SN. Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel. J Biomol Struct Dyn 2022;40:2395-406.
137. Boehmerle W, Zhang K, Sivula M, et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A 2007;104:11103-8.
138. Fu S, Hirte H, Welch S, et al. First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 2017;35:324-33.
139. Mikkelsen T, Lush R, Grossman SA, et al. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs 2007;25:259-63.
140. Holdhoff M, Ye X, Supko JG, et al. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol 2017;19:845-52.
141. Omuro A, Beal K, McNeill K, et al. Multicenter phase IB trial of carboxyamidotriazole orotate and temozolomide for recurrent and newly diagnosed glioblastoma and other anaplastic gliomas. J Clin Oncol 2018;36:1702-9.
